ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Shattuck Labs, Inc. | STTK | United States of America | $314.77M | 436 |
| LUMOSA THERAPEUTICS CO., LTD. | 6535 | Taiwan | $503.97M | 1,353 |
| Entrada Therapeutics, Inc. | TRDA | United States of America | $299.70M | 489 |
| Invivyd, Inc. | IVVD | United States of America | $482.20M | 489 |
| Contineum Therapeutics, Inc. | CTNM | United States of America | $546.96M | 202 |
| 4D Molecular Therapeutics, Inc. | FDMT | United States of America | $475.29M | 487 |
| Zentalis Pharmaceuticals, Inc. | ZNTL | United States of America | $284.75M | 587 |
| Lyell Immunopharma, Inc. | LYEL | United States of America | $279.31M | 380 |
| Larimar Therapeutics, Inc. | LRMR | United States of America | $467.47M | 701 |
| GENFIT | GNFT | France | $588.96M | 751 |
| Aclaris Therapeutics, Inc. | ACRS | United States of America | $769.55M | 914 |
| Climb Bio, Inc. | CLYM | United States of America | $801.68M | 334 |
| Absci Corp | ABSI | United States of America | $1.28B | 415 |
| Atea Pharmaceuticals, Inc. | AVIR | United States of America | $340.12M | 364 |
| Kyverna Therapeutics, Inc. | KYTX | United States of America | $454.14M | 206 |
| enGene Therapeutics Inc. | ENGN | Canada | $456.20M | 296 |
| Eupraxia Pharmaceuticals Inc. | EPRX | Canada | $413.52M | 460 |
| Fulcrum Therapeutics, Inc. | FULC | United States of America | $245.88M | 545 |
| REGENXBIO Inc. | RGNX | United States of America | $555.23M | 851 |
| Armata Pharmaceuticals, Inc. | ARMP | United States of America | $146.48M | 1,115 |
| Lexeo Therapeutics, Inc. | LXEO | United States of America | $324.29M | 393 |
| ASSEMBLY BIOSCIENCES, INC. | ASMB | United States of America | $533.88M | 823 |
| Altimmune, Inc. | ALT | United States of America | $530.91M | 1,417 |
| Perspective Therapeutics, Inc. | CATX | United States of America | $345.56M | 1,140 |
| Adlai Nortye Ltd. | ANL | Cayman Islands | $434.68M | 110 |
| Immix Biopharma, Inc. | IMMX | United States of America | $789.50M | 241 |
| Aura Biosciences, Inc. | AURA | United States of America | $707.51M | 398 |
| Cybin Inc. | HELP | Canada | $413.12M | 1,179 |
| Century Therapeutics, Inc. | IPSC | United States of America | $394.98M | 445 |
| XOMA Royalty Corp | XOMA | United States of America | $392.98M | 1,555 |
| Benitec Biopharma Inc. | BNTC | United States of America | $456.23M | 306 |
| Lineage Cell Therapeutics Inc. | LCTX | United States of America | $269.93M | 3,362 |
| ENANTA PHARMACEUTICALS INC | ENTA | United States of America | $398.37M | 877 |
| ROCKET PHARMACEUTICALS, INC. | RCKT | United States of America | $365.80M | 988 |
| Polaris Group | 6550 | Taiwan | $374.26M | 1,268 |
| AVACTA GROUP PLC | AVCT | United Kingdom | $370.79M | 759 |
| PureTech Health plc | PRTC | United Kingdom | $426.76M | 1,384 |
| Forte Biosciences, Inc. | FBRX | United States of America | $903.53M | 596 |
| Prestige BioPharma Limited | 950210 | South Korea | $211.47M | 266 |
| Neumora Therapeutics, Inc. | NMRA | United States of America | $342.78M | 277 |
| DiaMedica Therapeutics Inc. | DMAC | United States of America | $413.29M | 450 |
| Candel Therapeutics, Inc. | CADL | United States of America | $695.33M | 437 |
| Cellectis | ALCLS | France | $321.79M | 1,430 |
| Monopar Therapeutics | MNPR | United States of America | $356.62M | 525 |
| Immuneering Corp | IMRX | United States of America | $276.90M | 344 |
| Ovid Therapeutics Inc. | OVID | United States of America | $447.94M | 547 |
| BICYCLE THERAPEUTICS PLC | BCYC | United Kingdom | $327.41M | 673 |
| Keros Therapeutics, Inc. | KROS | United States of America | $336.35M | 556 |
| Avalo Therapeutics, Inc. | AVTX | United States of America | $984.82M | 1,191 |
| Oryzon Genomics S.A. | ORY | Spain | $323.55M | 158 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.